Kūʻai kūʻai kūʻai mai nā mea kūʻai aku CAS 782487-28-9 Rosiptor maikaʻi maikaʻi ke kumu kūʻai maikaʻi loa ʻo ke kūʻai aku ʻana i ka palekana palekana hoʻouna kiʻekiʻe maʻemaʻe 99%-kope.

ʻO ka huahana mua o semaglutide i hoʻomohala ʻia e Novo Nordisk a hōʻike ʻia no nā pākeke me ka maʻi diabetes type 2. ʻO ka inoa kālepa o ka huahana injection ʻo Ozempic®, hiki ke hoʻohana i hoʻokahi manawa i ka pule. Ua ʻae ʻia no ke kūʻai ʻana e ka US Food and Drug Administration (FDA) ma Dekemaba 5, 2017, a e ka European Medicines Agency (EMA) ma Pepeluali 8, 2018. PMDA) ma Malaki 23, 2018. Ua waiho ʻia kahi noi kūʻai aku i ka China Medical Products Administration (NMPA) ma ʻApelila 4, 2020, a ke nānā ʻia nei a ʻae ʻia. Ua ʻae ʻia ka inoa inoa puke chemicalbook o ka huahana papa waha, Rybelsus®, e ka FDA ma Kepakemapa 20, 2019, ka European EMA i Malaki 2020, a me ka PMDA Iapana i Iune 2020. ʻO ia ka lāʻau GLP-1 waha mua loa ma ka honua. Hiki ke hoʻohana ʻia ʻo Semaglutide (0.5 mg a i ʻole 1 mg injection) e mālama i ka maʻi diabetes type 2 i nā pākeke. ʻO kēia lāʻau lapaʻau he glucagon-like peptide (GLP-1) receptor agonist, kahi e hoʻoulu ai i ka huna ʻana o ka insulin a hoʻemi i ka huna ʻana o ka glucagon. ʻO ka hapalua o ke ola o ka hoʻopaʻa ʻana i ka albumin koko he 1 pule, no laila pono e lawelawe ʻia i hoʻokahi manawa i ka pule me kahi peni prefilled. Kōkua i ka ʻai a me ka hoʻoikaika kino e hoʻomaikaʻi i ke kō koko koko i ka poʻe mākua me ka maʻi diabetes type 2.